- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
VRIO Analysis of Stride Pharmaceuticals Employment Equity for Corporate Performance
Posted by Zachary Edwards on Mar-22-2018
The VRIO Analysis of Stride Pharmaceuticals Employment Equity for Corporate Performance will look at each of its internal resources one by one to assess whether these provide sustained competitive advantage. The Stride Pharmaceuticals Employment Equity for Corporate Performance VRIO Analysis also mentions at each stage whether these resources could be improved to provide a greater competitive advantage. Lastly, the resources analysed are summarised as to whether they offer sustained competitive advantage, has an unused competitive advantage, temporary competitive advantage, competitive parity or competitive disadvantage.
Valuable
- The Stride Pharmaceuticals Employment Equity for Corporate Performance VRIO Analysis shows that the financial resources of Stride Pharmaceuticals Employment Equity for Corporate Performance are highly valuable as these help in investing into external opportunities that arise. These also help Stride Pharmaceuticals Employment Equity for Corporate Performance in combating external threats.
- According to the VRIO Analysis of Stride Pharmaceuticals Employment Equity for Corporate Performance, its local food products are a valuable resource as these are highly differentiated. This makes the perceived value for these by customers high. These are also valued more than the competition by customers due to the differentiation in these products.
- The Stride Pharmaceuticals Employment Equity for Corporate Performance VRIO Analysis shows that Stride Pharmaceuticals Employment Equity for Corporate Performance's employees are a valuable resource to the firm. A significant portion of the workforce is highly trained, and this leads to more productive output for the organisation. The employees are also loyal, and retention levels for the organisation are high. All of this translates into greater value for the end consumers of Stride Pharmaceuticals Employment Equity for Corporate Performance's products.
- According to the VRIO Analysis of Stride Pharmaceuticals Employment Equity for Corporate Performance, its patents are a valuable resource as these allow the firm to sell its products without competitive interference. This results in greater revenue for Stride Pharmaceuticals Employment Equity for Corporate Performance. These patents also provide Stride Pharmaceuticals Employment Equity for Corporate Performance with licensing revenue when it licenses these patents out to other manufacturers.
- The Stride Pharmaceuticals Employment Equity for Corporate Performance VRIO Analysis shows that Stride Pharmaceuticals Employment Equity for Corporate Performance’s distribution network is a valuable resource. This helps it in reaching out to more and more customers. This ensures greater revenues for Stride Pharmaceuticals Employment Equity for Corporate Performance. It also ensures that promotion activities translate into sales as the products are easily available.
- According to the VRIO Analysis of Stride Pharmaceuticals Employment Equity for Corporate Performance, its cost structure is not a valuable resource. This is because the methods of production lead to greater costs than that of competition, which affects the overall profits of the firm. Therefore, its cost structure is a competitive disadvantage that needs to be worked on.
- The Stride Pharmaceuticals Employment Equity for Corporate Performance VRIO Analysis shows that the research and development at Stride Pharmaceuticals Employment Equity for Corporate Performance is not a valuable resource. This is because research and development are costing more than the benefits it provides in the form of innovation. There have been very few innovative features and breakthrough products in the past few years. Therefore, research and development are a competitive disadvantage for Stride Pharmaceuticals Employment Equity for Corporate Performance. It is recommended that the research and development teams are improved, and costs are cut for these.
Rare
- The financial resources of Stride Pharmaceuticals Employment Equity for Corporate Performance are found to be rare according to the VRIO Analysis of Stride Pharmaceuticals Employment Equity for Corporate Performance. Strong financial resources are only possessed by a few companies in the industry.
- The local food products are found to be not rare as identified by Stride Pharmaceuticals Employment Equity for Corporate Performance VRIO Analysis. These are easily provided in the market by other competitors. This means that competitors can use these resources in the same way as Stride Pharmaceuticals Employment Equity for Corporate Performance and inhibit competitive advantage. This means that the local food products result in competitive parity for Stride Pharmaceuticals Employment Equity for Corporate Performance. As this resource is valuable, Stride Pharmaceuticals Employment Equity for Corporate Performance can still make use of this resource.
- The employees of Stride Pharmaceuticals Employment Equity for Corporate Performance are a rare resource as identified by the VRIO Analysis of Stride Pharmaceuticals Employment Equity for Corporate Performance. These employees are highly trained and skilled, which is not the case with employees in other firms. The better compensation and work environment ensure that these employees do not leave for other firms.
- The patents of Stride Pharmaceuticals Employment Equity for Corporate Performance are a rare resource as identified by the Stride Pharmaceuticals Employment Equity for Corporate Performance VRIO Analysis. These patents are not easily available and are not possessed by competitors. This allows Stride Pharmaceuticals Employment Equity for Corporate Performance to use them without interference from the competition.
- The distribution network of Stride Pharmaceuticals Employment Equity for Corporate Performance is a rare resource as identified by the VRIO Analysis of Stride Pharmaceuticals Employment Equity for Corporate Performance. This is because competitors would require a lot of investment and time to come up with a better distribution network than that of Stride Pharmaceuticals Employment Equity for Corporate Performance. These are also possessed by very few firms in the industry.
Imitable
- The financial resources of Stride Pharmaceuticals Employment Equity for Corporate Performance are costly to imitate as identified by the Stride Pharmaceuticals Employment Equity for Corporate Performance VRIO Analysis. These resources have been acquired by the company through prolonged profits over the years. New entrants and competitors would require similar profits for a long period of time to accumulate these amounts of financial resources.
- The local food products are not that costly to imitate as identified by the VRIO Analysis of Stride Pharmaceuticals Employment Equity for Corporate Performance. These can be acquired by competitors as well if they invest a significant amount in research and development. These also do not require years long experience. Therefore, the local food products by Stride Pharmaceuticals Employment Equity for Corporate Performance provide it with a temporary competitive advantage that competitors can too acquire in the long run.
- The employees of Stride Pharmaceuticals Employment Equity for Corporate Performance are also not costly to imitate as identified by the Stride Pharmaceuticals Employment Equity for Corporate Performance VRIO Analysis. This is because other firms can also train their employees to improve their skills. These companies can also hire employees from Stride Pharmaceuticals Employment Equity for Corporate Performance by offering better compensation packages, work environment, benefits, growth opportunities etc. This makes the employees of Stride Pharmaceuticals Employment Equity for Corporate Performance a resource that provides a temporary competitive advantage. Competition can acquire these in the future.
- The patents of Stride Pharmaceuticals Employment Equity for Corporate Performance are very difficult to imitate as identified by the VRIO Analysis of Stride Pharmaceuticals Employment Equity for Corporate Performance. This is because it is not legally allowed to imitate a patented product. Similar resources to be developed and getting a patent for them is also a costly process.
- The distribution network of Stride Pharmaceuticals Employment Equity for Corporate Performance is also very costly to imitate by competition as identified by the Stride Pharmaceuticals Employment Equity for Corporate Performance VRIO Analysis. This has been developed over the years gradually by Stride Pharmaceuticals Employment Equity for Corporate Performance. Competitors would have to invest a significant amount if they are to imitate a similar distribution system.
Organisation
- The financial resources of Stride Pharmaceuticals Employment Equity for Corporate Performance are organised to capture value as identified by the VRIO Analysis of Stride Pharmaceuticals Employment Equity for Corporate Performance. These resources are used strategically to invest in the right places; making use of opportunities and combatting threats. Therefore, these resources prove to be a source of sustained competitive advantage for Stride Pharmaceuticals Employment Equity for Corporate Performance.
- The Patents of Stride Pharmaceuticals Employment Equity for Corporate Performance are not well organised as identified by the Stride Pharmaceuticals Employment Equity for Corporate Performance VRIO Analysis. This means that the organisation is not using these patents to their full potential. An unused competitive advantage exists that can be changed into a sustainable competitive advantage if Stride Pharmaceuticals Employment Equity for Corporate Performance starts selling patented products before the patents expire.
- The distribution network of Stride Pharmaceuticals Employment Equity for Corporate Performance is organised as identified by the VRIO Analysis of Stride Pharmaceuticals Employment Equity for Corporate Performance. Stride Pharmaceuticals Employment Equity for Corporate Performance uses this network to reach out to its customers by ensuring that products are available on all of its outlets. Therefore, these resources prove to be a source of sustained competitive advantage for Stride Pharmaceuticals Employment Equity for Corporate Performance.
From the VRIO Analysis of Stride Pharmaceuticals Employment Equity for Corporate Performance, it was identified that the financial resources and distribution network provide a sustained competitive advantage. The patents are a source of unused competitive advantage. There exists a temporary competitive advantage for employees. There exists a competitive parity for local food products. Lastly, the cost structure of Stride Pharmaceuticals Employment Equity for Corporate Performance is a competitive disadvantage. Research and Development is also a competitive disadvantage.
Warning! This article is only an example and cannot be used for research or reference purposes. If you need help with something similar, please submit your details here.
Abigail Archer
5.0
I secretly land on this service whenever the teacher assigns an assignment and become the most obedient and decent student by submitting the paper on time.
Charles Joye
5.0
The citation that the expert utilized in the paper, the professor, rectified it with good words and great scores. I’ll be with you if you guys are like this.
Madie Bbrenden
5.0
Undoubtedly this service is the best in the groups. The document was regardless of any mistake
Anbar Jassem
5.0
I wrote the assignment and delegated it to this service for proofreading. The writer was skilled enough and edited the paper where it was required. I'm well pleased with the modified content. Thank you!
Next Articles
- In Line With The Business: A Human Resources Model For Nedcor Bank Vrio Analysis
- Lechabile: IT As A People Business Vrio Analysis
- Strategising To Keep Otis SA At The Top Vrio Analysis
- Knowledge Management: Designing A Strategy For Bsw Vrio Analysis
- Old Mutual: Demutualisation And Listing Vrio Analysis
- War On HIV/AIDS Vrio Analysis
- Rob Angel: Leading Engen To Empowerment Vrio Analysis
- Hansa Pilsener: From Niche To Mainstream Brand Vrio Analysis
- FC Schalke 04 ESports Decision Making In A Changing Ecosystem Vrio Analysis
- The China Gambit: When Chinese VCs Knock On A German Start Up's Door Vrio Analysis
Previous Articles
- Identifying Best Practice: Metropolitan And HIV/AIDS Vrio Analysis
- HIV/AIDS In South Africa: What Is An Adequate Response? Vrio Analysis
- Amanz'abantu: Water For The People Vrio Analysis
- Massmart: Growing The Growth Engine Vrio Analysis
- Mozambique And The Hipc Initiative: The Politics Of Debt Vrio Analysis
- South African Breweries: Achieving Growth In The Global Beer Market Vrio Analysis
- Background Note To Dimension Data Vrio Analysis
- Didata: Globalising At Warp Speed Vrio Analysis
- Sasol/AECI: The Right Chemistry For A Merger? Vrio Analysis
- Nando's International: Taking Chicken To The World Vrio Analysis
Be a great writer or hire a greater one!
Academic writing has no room for errors and mistakes. If you have BIG dreams to score BIG, think out of the box and hire Case48 with BIG enough reputation.
Our Guarantees
Interesting Fact
Most recent surveys suggest that around 76 % students try professional academic writing services at least once in their lifetime!